此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

酮康唑治疗正在进行的 EGFR 抑制剂引起的皮疹参与者

2026年9月17日 更新者:Mayo Clinic

探索抗雄激素酮康唑治疗表皮生长因子受体 (EGFR) 抑制剂诱发皮疹患者的双盲、安慰剂对照试验

This early phase I trial studies the side effects of ketoconazole and how well it works in treating participants with ongoing EGFR inhibitor-induced rash. Ketoconazole may reduce the symptoms related to EGFR inhibitor therapy and improve EGFR inhibitor-induced rash.

研究概览

详细说明

PRIMARY OBJECTIVES:

I. To demonstrate that topical ketoconazole, an anti-androgen, palliates EGFR inhibitor-induced rash within a group of racially diverse cancer patients.

II. To explore the role of ribonucleic acid (RNA) sequencing to identify other targets that might be used at a later date for rash palliation.

III. To evaluate toxicities associated with topical ketoconazole.

OUTLINE: Participants are randomized to 1 of 2 arms.

ARM I: Participants apply ketoconazole topically twice daily (BID) on days 1-28.

ARM II: Participants apply placebo topically BID on days 1-28.

After completion of study treatment, participants are followed up at 1 week.

研究类型

介入性

注册 (实际的)

58

阶段

  • 第一阶段早期

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Illinois
      • Danville、Illinois、美国、61832
        • Carle on Vermilion
      • Urbana、Illinois、美国、61801
        • Carle Cancer Center
    • Minnesota
      • Rochester、Minnesota、美国、55905
        • Mayo Clinic in Rochester
      • Saint Louis Park、Minnesota、美国、55426
        • Park Nicollet Frauenshuh Cancer Center
      • Saint Paul、Minnesota、美国、55101
        • Regions Hospital
    • New York
      • Rochester、New York、美国、14642
        • University of Rochester

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Patient has developed a rash or symptoms of a rash (cutaneous burning) characteristic of an EGFR inhibitor (health-care provider report of the rash with no other documentation is permitted)
  • Patient is anticipated to continue for at least 28 days with an EGFR inhibitor or restart =< 14 days of registration and continue for at least 28 days
  • Mayo only: Patient is willing to provide a skin biopsy for correlative research; Note: Can be waived with permission of study chair (documentation such as an email must be provided)
  • Patient must complete baseline quality of life (QOL) packet

Exclusion Criteria:

  • Patient has a prior allergy or intolerance of ketoconazole
  • Patient has an allergy or intolerance to sulfites

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:支持治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Arm I (ketoconazole)

Participants apply ketoconazole topically BID on days 1-28.

Correlative studies

Ancillary studies

其他名称:
  • 生活质量评估

Ancillary studies

Applied topically

其他名称:
  • 尼佐拉尔
  • 真菌类
  • 真菌性
  • 酮皮
  • 酮抑素
  • 东方M
  • Panfungol
  • R-41400
  • Xolegel
安慰剂比较:Arm II (placebo)

Participants apply placebo topically BID on days 1-28.

Correlative studies

Ancillary studies

其他名称:
  • 生活质量评估

Ancillary studies

Applied topically

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Proportion of patients who report an improvement in skin rash
大体时间:Up to 4 weeks

Assessed by Skindex-16. Will be estimated using the cumulative incidence function with time to improvement defined as the time from randomization to the first of the two consecutive weeks of improved symptom. The cumulative incidence of rash improvement after 4 weeks of treatment will be summarized separately by treatment arm. The difference in rash improvement incidences will be estimated and will be compared using two-sample Z-test.

Up to 4 weeks

次要结果测量

结果测量
措施说明
大体时间
Incidence of skin toxicity
大体时间:Up to 4 weeks

As measured by the Skindex-16. Responses to the Skindex-16 will be categorized into three subscales: symptom, emotional, and functional. Analysis of the total scales and subscales of the Skindex-16 will involve a t-test and Wilcoxon rank sum procedures (as appropriate) at each time point as well as linear mixed modeling. Descriptive factors will be used as covariates in the modeling analysis. The change from baseline in the total score and subscales of the Skindex-16 will be compared between two arms by a two-sample, two-sided t-test. If there is evidence of non-normality (via Shapiro-Wilk testing), a non-parametric procedure such as Wilcoxon rank sum will be used.

Up to 4 weeks
Incidence of skin toxicity
大体时间:Up to 4 weeks

As measured by the Skin Toxicity Assessment Tool (STAT). Responses to the STAT will be categorized into three subscales: symptom, emotional, and functional. Analysis of the total scales and subscales of the STAT will involve a t-test and Wilcoxon rank sum procedures (as appropriate) at each time point as well as linear mixed modeling. Descriptive factors will be used as covariates in the modeling analysis. The change from baseline in the total score and subscales of the STAT will be compared between two arms by a two-sample, two-sided t-test. If there is evidence of non-normality (via Shapiro-Wilk testing), a non-parametric procedure such as Wilcoxon rank sum will be used.

Up to 4 weeks
Incidence of adverse events for ketoconazole
大体时间:Up to 4 weeks

Adverse events will be tabulated by treatment arm. Frequencies of various types of adverse events (AEs) will be compared using Fisher's exact test. Will explore the difference in reliability of the direct versus (vs.) indirect AE attribution approaches in the placebo arm.

Up to 4 weeks

其他结果措施

结果测量
措施说明
大体时间
Change in PLA2G4D, PLOD2, and SALL4
大体时间:Baseline up to 4 weeks

Assessed by ribonucleic acid (RNA) sequencing. Will explore the association between baseline/change in PLA2G4D, PLOD2, and SALL4 with rash improvement. Baseline gene expression level and change from baseline in gene expression level for the androgen-related genes such as PLA2G4D, PLOD2, and SALL4 will be compared between arms by t-test and Wilcoxon rank sum procedures (as appropriate). Mixed Models for Logistic Regression will also be implemented to explore the association between PLA2G4D, PLOD2, and SALL4 with rash improvement by adjusting the baseline gene expression level and change from baseline in gene expression levels for each gene. Descriptive factors will be used as covariates in the modeling analysis.

Baseline up to 4 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Aminah Jatoi, M.D.、Mayo Clinic
  • 首席研究员:Elizabeth J. Cathcart-Rake, M.D.、Mayo Clinic

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2018年9月25日

初级完成 (实际的)

2024年9月15日

研究完成 (实际的)

2024年9月15日

研究注册日期

首次提交

2018年3月6日

首先提交符合 QC 标准的

2018年3月19日

首次发布 (实际的)

2018年3月20日

研究记录更新

最后更新发布 (实际的)

2026年9月21日

上次提交的符合 QC 标准的更新

2026年9月17日

最后验证

2025年10月1日

更多信息

与本研究相关的术语

其他研究编号

  • MC17C1
  • MC17C1 (其他标识符:Mayo Clinic in Rochester)
  • NCI-2018-00355 (注册表标识符:CTRP (Clinical Trial Reporting Program))
  • R01CA207183 (美国 NIH 拨款/合同)
  • 17-007786 (其他标识符:Mayo Clinic Institutional Review Board)

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅